Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514765 | 1.00 | TGFBR1 (0.43) | TGFBR1AAK1CYP3A4PIK3C3TGFBR2 | |
| SCHEMBL20782235 | 0.93 | DHODH (0.38) | TGFBR1AAK1CYP3A4PIK3C3 | |
| SCHEMBL20765639 | 0.92 | AAK1 (0.43) | AAK1CYP3A4PIK3C3 | |
| SCHEMBL30514775 | 0.92 | AAK1 (0.43) | AAK1CYP3A4PIK3C3 | |
| SCHEMBL20765313 | 0.88 | PIK3C3 (0.48) | TGFBR1AAK1CYP3A4PIK3C3ADORA3 | |
| SCHEMBL30514769 | 0.88 | PIK3C3 (0.48) | TGFBR1AAK1CYP3A4PIK3C3ADORA3 | |
| SCHEMBL30514770 | 0.88 | PIK3C3 (0.46) | TGFBR1AAK1CYP3A4PIK3C3TGFBR2 | |
| SCHEMBL20782477 | 0.88 | PIK3C3 (0.46) | TGFBR1AAK1CYP3A4PIK3C3TGFBR2 | |
| SCHEMBL20764792 | 0.83 | AAK1 (0.49) | TGFBR1AAK1CYP3A4PIK3C3 | |
| SCHEMBL20776135 | 0.83 | PIK3C3 (0.41) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903526-A | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116891431-A | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-111094244-B | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-07-11 | — | — | CN | disclosed |
| EP-4056556-A1 | PYRIDYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-09-14 | — | — | EP | disclosed |
| US-20220218688-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20220218688-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-07-14 | — | — | US | disclosed |
| EP-3672941-B1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-02-09 | — | — | EP | disclosed |
| EP-3672941-B1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-02-09 | — | — | EP | disclosed |
| US-11219618-B2 | Pyridylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2022-01-11 | — | — | US | disclosed |
| US-11219618-B2 | Pyridylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2022-01-11 | — | — | US | disclosed |
| US-20200289496-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2020-09-17 | — | — | US | disclosed |
| US-20200289496-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2020-09-17 | — | — | US | disclosed |
| EP-3672941-A1 | PYRIDYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| CN-111094244-A | Pyridylpyridone compounds | 思普瑞特生物科学公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019038387-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038387-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11219618-B2 | Pyridylpyridone compounds | PDXK, PLPBP, PNPO | TGFBR1 302/4885AAK1 1239/4885CYP3A4 573/4885 |
| US-20200289496-A1 | PYRIDYLPYRIDONE COMPOUNDS | PDXK, PLPBP, PNPO | TGFBR1 302/4885AAK1 1239/4885CYP3A4 573/4885 |
| US-20220218688-A1 | PYRIDYLPYRIDONE COMPOUNDS | PDXK, PLPBP, PNPO | TGFBR1 302/4885AAK1 1239/4885CYP3A4 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.